Effect of lowering of homocysteine levels on inflammatory markers: A randomized controlled trial

Archives of Internal Medicine

Volumn 165, Issue 12, 2005, Pages 1388-1394

  Durga, Jane ^a,b,d   Van Tits, L J H ^c   Schouten, Evert G ^a   Kok, Frans J ^a   Verhoef, Petra ^a,b  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FOLIC ACID; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; OXIDIZED LOW DENSITY LIPOPROTEIN; ANTIANEMIC AGENT; AUTOANTIBODY; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLIC ACID BLOOD LEVEL; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VITAMIN SUPPLEMENTATION; AGED; BLOOD; DIET SUPPLEMENTATION; METABOLISM; MIDDLE AGED;

AGED; AUTOANTIBODIES; C-REACTIVE PROTEIN; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; FOLIC ACID; HEMATINICS; HOMOCYSTEINE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LIPOPROTEINS, LDL; MALE; MIDDLE AGED;

EID: 22144473356     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.165.12.1388     Document Type: Article

References (47)

1. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
2. Symons JD, Mullick AE, Ensunsa JL, Ma AA, Rutledge JC. Hyperhomocysteinemia evoked by folate depletion: effects on coronary and carotid arterial function. Arterioscler Thromb Vasc Biol. 2002;22:772-780.
3. Zhang R, Ma J, Xia M, Zhu H, Ling W. Mild hyperhomocysteinemia induced by feeding rats diets rich in methionine or deficient in folate promotes early atherosclerotic inflammatory processes. J Nutr. 2004;134:825-830.
4. Wang G, Woo CWH, Sung FL, Siow YL, O K. Increased monocyte adhesion to aortic endothelium in rats with hyperhomocysteinemia: role of chemokine and adhesion molecules. Arterioscler Thromb Vasc Biol. 2002;22:1777-1783.
5. Lee H, Kim HJ, Kim J, Chang N. Effects of dietary folic acid supplementation on cerebrovascular endothelial dysfunction in rats with induced hyperhomocysteinemia. Brain Res. 2004;996:139-147.
6. Powers RW, Majors AK, Cerula SL, Huber HA, Schmidt BP, Roberts JM. Changes in markers of vascular injury in response to transient hyperhomocysteinemia. Metabolism. 2003;52:501-507.
7. Holven KB, Scholz H, Halvorsen B, Aukrust P, Ose L, Nenseter MS. Hyperhomocysteinemic subjects have enhanced expression of lectin-like oxidized LDL receptor-1 in mononuclear cells. J Nutr. 2003;133:3588-3591.
8. Ambrosi P, Rolland PH, Bodard H, et al. Effects of folate supplementation in hyperhomocysteinemic pigs. J Am Coll Cardiol. 1999;34:274-279.
9. Hofmann MA, Lalla E, Lu Y, et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest. 2001;107:675-683.
10. Hackam DG, Peterson JC, Spence JD. What level of plasma homocyst(e)ine should be treated? effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 μmol/L.AmJ Hypertens. 2000;13:105-110.
11. Leeuwenberg JF, Smeets EF, Neefjes JJ, et al. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology. 1992;77:543-549.
12. van Tits LJ, de Waart F, Hak Lemmers HLM, et al. Effects of α-tocopherol on superoxide production and plasma intercellular adhesion molecule-1 and antibodies to oxidized LDL in chronic smokers. Free Radic Biol Med. 2001;30:1122-1129.
13. Klerk M, Durga J, Schouten EG, Kluft C, Kok FJ, Verhoef P. No effect of folic acid supplementation for 1 year on haemostatis markers of C-reactive protein in middleaged subjects. Thromb Haemost. In press.
14. Vermeulen EG, Rauwerda JA, van den Berg M, et al. Homocysteine-lowering treatment with folic acid plus vitamin B6 lowers urinary albumin excretion but not plasma markers of endothelial function or C-reactive protein: further analysis of secondary end-points of a randomized clinical trial. Eur J Clin Invest. 2003;33:209-215.
15. Chao C-L, Kuo T-L, Lee Y-T. Effects of methionine-induced hyperhomocysteinemia on endothelium-dependent vasodilation and oxidative status in healthy adults. Circulation. 2000;101:485-490.
16. Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? do the antioxidant trials conducted to date refute the hypothesis? Circulation. 2002;105:2107-2111.
17. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA. 2003;290:932-940.
18. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998;351:88-92.
19. Holvoet P, Harris TB, Tracy RP, et al. Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the Health, Aging, and Body Composition Study. Arterioscler Thromb Vasc Biol. 2003;23:1444-1448.
20. Puurunen M, Manttari M, Manninen V, et al. Antibody against oxidized lowdensity lipoprotein predicting myocardial infarction. Arch Intern Med. 1994;154:2605-2609.
21. Rossi GP, Cesari M, De Toni R, et al. Antibodies to oxidized low-density lipoproteins and angiographically assessed coronary artery disease in white patients. Circulation. 2003;108:2467-2472.
22. Lopes-Virella MF, Binzafar N, Rackley S, Takei A, La Via M, Virella G. The uptake of LDL-IC by human macrophages: predominant involvement of the FcγRI receptor. Atherosclerosis. 1997;135:161-170.
23. Shaw PX, Horkko S, Tsimikas S, et al. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol. 2001;21:1333-1339.
24. Miller YI, Chang M-K, Binder CJ, Shaw PX, Witztum JL. Oxidized low density lipoprotein and innate immune receptors. Curr Opin Lipidol. 2003;14:437-445.
25. Woodside JV, Young IS, Yarnell JW, et al. Antioxidants, but not B-group vitamins increase the resistance of low-density lipoprotein to oxidation: a randomized, factorial design, placebo-controlled trial. Atherosclerosis. 1999;144:419-427.
26. Doshi SN, McDowell IFW, Moat SJ, et al. Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide? Arterioscler Thromb Vasc Biol. 2001;21:1196-1202.
27. Moat SJ, Hill MH, McDowell IFW, et al. Reduction in plasma total homocysteine through increasing folate intake in healthy individuals is not associated with changes in measures of antioxidant activity or oxidant damage. Eur J Clin Nutr. 2003;57:483-489.
28. Clarke R, Harrison G, Richards S; VITAL Trial Collaborative Group. Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia. J Intern Med. 2003;254:67-75.
29. Chiarello PG, Vannucchi MTI, Moysés Neto M, Vannucchi H. Hyperhomocysteinemia and oxidative stress in hemodialysis: effects of supplementation with folic acid. Int J Vitam Nutr Res. 2003;73:431-438.
30. Bayés B, Pastor MC, Bonal J, Juncà J, Romero R. Homocysteine and lipid peroxidation in haemodialysis: role of folinic acid and vitamin E. Nephrol Dial Transplant. 2001;16:2172-2175.
31. Apeland T, Mansoor MA, Seljeflot I, Brønstad I, Gøransson L, Strandjord RE. Homocysteine, malondialdehyde and endothelial markers in dialysis patients during low-dose folinic acid therapy. J Intern Med. 2002;252:456-464.
32. Church TS, Earnest CP, Wood KA, Kampert JB. Reduction of C-reactive protein levels through use of a multivitamin. Am J Med. 2003;115:702-707.
33. Lowering blood homocysteine with folic acid based supplements: metaanalysis of randomised trials: Homocysteine Lowering Trialists' Collaboration. BMJ. 1998;316:894-898.
34. Jang Y, Lee JH, Kim OY, Park HY, Lee SY. Consumption of whole grain and legume powder reduces insulin demand, lipid peroxidation, and plasma homocysteine concentrations in patients with coronary artery disease: randomized controlled clinical trial. Arterioscler Thromb Vasc Biol. 2001;21:2065-2071.
35. Esposito K, Marfella R, Ciotola M, et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA. 2004;292:1440-1446.
36. Baker F, Picton D, Blackwood S, et al. Blinded comparison of folic acid and placebo in patients with ischemic heart disease: an outcome trial [abstract]. Circulation. 2002;106(suppl 2):II-741.
37. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565-575.
38. den Heijer M, Willems HPJ, Blom HJ, et al. Homocysteine lowering by B vitamins and the prevention of secondary deep-vein thrombosis and pulmonary embolism: a randomized placebo-controlled double-blind trial. In: Program and abstracts of the XIX Congress of the International Society on Thrombosis and Haemostasis; July 12-18, 2003; Birmingham, United Kingdom. Abstract OC161.
39. Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med. 2001;345:1593-1600.
40. Schnyder G, Roffi M, Flammer Y, et al. Effect of homocysteine-lowering therapy on restenosis after percutaneous coronary intervention for narrowings in small coronary arteries. Am J Cardiol. 2003;91:1265-1269.
41. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteinelowering therapy with folic acid, vitamin B12 and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA. 2002;288:973-979.
42. Till U, Jentsch A, Röhl P, et al. In patients at risk to cerebral ischemia an oral substitution with vitamin B6, B12 and folic acid leads to a significant decrease of the intima/media thickness of the carotids - results of a randomized, placebocontrolled trial [abstract]. J Inherit Metab Dis. 2003;26(suppl 1):13.
43. Marcucci R, Zanazzi M, Bertoni E, et al. Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients. Transplantation. 2003;75:1551-1555.
44. Lange H, Suryapranata H, De Luca G, et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med. 2004;350:2673-2681.
45. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke - a meta-analysis. JAMA. 2002;288:2015-2022.
46. Vermeulen EGJ, Stehouwer CDA, Twisk JWR, et al. Effect of homocysteinelowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomized, placebo-controlled trial. Lancet. 2000;355:517-522.
47. Vermeulen EGJ, Stehouwer CDA, Valk J, et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B on cerebrovascular atherosclerosis and white matter abnormalities as determined by MRA and MRI: a placebocontrolled randomized trial. Eur J Clin Invest. 2004;34:256-261.